Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib + tepotinib for EGFR-mutant NSCLC with MET overexpression or amplification after progression on lazertinib
KCT0009074Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2024
- Countries
- 1
- Sponsor
- Merck & Co.
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Drugs
- lazertinibtepotinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label trial of lazertinib and tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Started Jun 2024; status: recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
Beyond the preview
Go deeper on KCT0009074.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009074.